Aptahem AB is a Swedish-based biotechnology company that develops innovative aptamer-based drugs targeting inflammation and coagulation for the treatment of life-threatening conditions. The portfolio under development consists of multifunctional aptamer (synthetic constructed nucleic acid polymers) drug candidates with anti-coagulant, immunostimulant and anti-inflammatory properties.
The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by the severe inflammatory response that leads to organ and tissue damage in sepsis patients. The multi-functional profile of Apta-1 has shown to improve the survival of animals in a dose dependent manner in a lethal sepsis model in an unprecedented way. Aptahem is also investigating a second candidate, Apta-2, for the treatment of inflammatory diseases.
The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.
State of Ownership
Director of Corporate Development at Neural Analytics, Neural Analytics
Business Development Executive, Nature Publishing Group, Springer Nature